Galapagos tries to avoid being acquired by Gilead

The Dutch economic and financial daily Het Financieele Dagblad has published today a front-page article reporting that Belgium-based biotech Galapagos is looking for an important shareholder protecting it from Gilead.
Gilead already owns 13% of the company. Galapagos CEO Van de Stolpe is looking for an European pharmaceutical group willing to acquire a minimum 10% of its shares, in order to avoid Gilead increasing its stake. A new shareholder would make acquiring Gilead more difficult, since the Belgian law would protect the new shareholder, in that it could not be forced to to sell its shares. Van de Stolpe has recently said he wishes that Gilead remains European and is not taken over by a US competitor. Additionally, he rules out a takeover attempt by Gilead in a short time. Galapagos has a market capitalization of $4.63bn. It started trading with a 2.6% rise today (Amsterdam).
(Source: Het Financieele Dagblad)